scPharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
scPharmaceuticals Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q3 2024.
  • scPharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.23M, a 4.22% decline year-over-year.
  • scPharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $5.57M, a 33.4% increase year-over-year.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4.86M, a 71.1% increase from 2022.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.84M, a 19.9% increase from 2021.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.37M, a 18.3% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $5.57M $1.23M -$54K -4.22% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $5.63M $1.49M +$312K +26.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $5.32M $1.44M +$460K +46.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $4.86M $1.42M +$679K +92.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 $4.18M $1.28M +$496K +63.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $3.68M $1.18M +$499K +73.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $3.18M $980K +$344K +54.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $2.84M $737K +$100K +15.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 $2.74M $785K +$166K +26.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $2.57M $680K +$91K +15.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $2.48M $636K +$115K +22.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.37M $637K +$510K +402% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 $1.86M $619K -$125K -16.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $1.98M $589K -$32K -5.15% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $2.01M $521K +$13K +2.56% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $2M $127K -$308K -70.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 $2.31M $744K +$411K +123% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $1.9M $621K +$295K +90.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $1.6M $508K +$153K +43.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $1.45M $435K -$18K -3.97% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 $1.47M $333K -$230K -40.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $1.7M $326K -$171K -34.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $1.87M $355K -$267K -42.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 $2.14M $453K +$76K +20.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-24
Q3 2018 $2.06M $563K +$329K +141% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $1.73M $497K +$269K +118% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $1.46M $622K +$514K +476% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $947K $377K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-21
Q3 2017 $234K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $228K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 $108K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.